A standard urine toxicology test screens for five to twelve classes of drugs, depending on the panel ordered. The most common version, the 5-panel test, checks for marijuana, cocaine, opiates, amphetamines/methamphetamines, and phencyclidine (PCP). Larger panels add substances like benzodiazepines, barbiturates, methadone, and ecstasy. The specific drugs covered depend on whether the test is for a workplace requirement, a clinical setting, or a legal proceeding.
The Standard 5-Panel Test
The 5-panel urine drug test is the baseline for all federally mandated workplace testing, including Department of Transportation screenings. It covers five drug classes:
- Marijuana (THC): Detects the main breakdown product of cannabis.
- Cocaine: Detects a metabolite called benzoylecgonine, which stays in urine longer than cocaine itself.
- Opiates: Covers opium derivatives like codeine and morphine.
- Amphetamines/methamphetamines: Includes prescription stimulants and illicit methamphetamine.
- Phencyclidine (PCP): An older hallucinogenic drug still included because of its severity of effects.
Many employers stick with this panel because it satisfies federal requirements. However, companies can add their own testing beyond these five classes under a separate, non-DOT policy.
Expanded 10-Panel and 12-Panel Tests
When a provider or employer orders a broader screen, additional drug classes are layered on top of the standard five. A typical 10-panel test adds barbiturates, benzodiazepines (anti-anxiety medications like diazepam), methadone, methaqualone, and propoxyphene. A 12-panel test often includes ecstasy (MDMA) and extended opioids like oxycodone or buprenorphine.
Federal workplace guidelines were updated to reflect the current drug landscape. The mandatory HHS testing panel now includes separate categories for hydrocodone/hydromorphone, oxycodone/oxymorphone, fentanyl, and heroin (detected through its unique marker, 6-acetylmorphine), along with MDMA/MDA. This matters because older “opiate” screens were designed around natural opium derivatives and could miss synthetic or semi-synthetic opioids entirely.
Specialized Pain Management Panels
In clinical settings, particularly pain clinics or addiction treatment programs, providers often order expanded panels that go well beyond the standard workplace screen. The University of Iowa’s expanded urine toxicology panel, for example, tests for buprenorphine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine, methadone, morphine, naloxone, oxycodone, oxymorphone, tapentadol, and tramadol. These panels help clinicians verify that a patient is taking prescribed medications and not supplementing with other substances. They use more sensitive technology (liquid chromatography with tandem mass spectrometry) that can identify specific drugs rather than just drug families.
How the Test Actually Works
Urine toxicology testing is a two-step process. The first step is an immunoassay, a rapid screening technique that uses antibodies to detect drug metabolites. It’s fast, relatively inexpensive, and good for sorting samples into “negative” and “presumptive positive” categories. But it has real limitations. Immunoassays work by recognizing molecular shapes, which means structurally similar compounds can trigger a positive result even when the target drug isn’t present.
Any sample that screens positive on immunoassay goes through confirmatory testing using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry. These methods physically separate and identify individual molecules in the sample, making them far more accurate. GC-MS can detect substances at lower concentrations and distinguish between closely related compounds that immunoassays lump together. In forensic and legal contexts, confirmatory testing is required before results carry any weight.
Cutoff Levels That Determine a Positive Result
A urine drug test doesn’t simply detect “any trace” of a substance. Each drug has a set concentration threshold, measured in nanograms per milliliter (ng/mL), that must be reached before the test reports a positive. These cutoffs are set deliberately to reduce false positives from passive exposure or trace contamination.
For the initial immunoassay screen, the federal thresholds are: marijuana metabolite at 50 ng/mL, cocaine metabolite at 150 ng/mL, codeine/morphine at 2,000 ng/mL, amphetamine/methamphetamine at 500 ng/mL, and PCP at 25 ng/mL. Fentanyl has an exceptionally low cutoff of just 1 ng/mL, reflecting both its potency and the tiny amounts needed to produce effects.
Confirmatory tests use lower cutoffs for most substances. Marijuana drops to 15 ng/mL, cocaine to 100 ng/mL, and amphetamines to 250 ng/mL. This means a sample could pass the initial screen but still test positive on confirmation if the lab runs confirmatory testing at these tighter thresholds. The two-step system balances speed with accuracy.
Common Causes of False Positives
One of the most practical things to know about urine toxicology is that several ordinary medications can trigger false positive results on the initial immunoassay screen. This is a well-documented problem across every drug class.
Pseudoephedrine (the decongestant in many cold medicines), bupropion (an antidepressant and smoking cessation aid), and phentermine (a weight loss medication) can all produce false positives for amphetamines. Any pharmaceutical built on a core chemical structure called phenylethylamine can potentially cross-react with the amphetamine assay.
For opiates, common cough suppressants containing dextromethorphan, the antihistamine diphenhydramine (Benadryl), and even poppy seeds have caused false positives. PCP false positives can be triggered by dextromethorphan, diphenhydramine, ketamine, ibuprofen, and the antidepressant venlafaxine. Ibuprofen and naproxen have also been reported to cause false positives on both barbiturate and benzodiazepine screens.
Cannabis is considered one of the more specific assays, but false positives have still been reported with promethazine (an anti-nausea medication), certain NSAIDs, and even some baby wash products. If you’re taking any medication that could interfere, disclosing it before the test lets the lab account for potential cross-reactivity. Confirmatory GC-MS testing will almost always sort out a true positive from a false one.
Specimen Validity Checks
Beyond testing for drugs, labs also check whether the urine sample itself is legitimate. Every specimen is evaluated for creatinine concentration, pH, and (when creatinine is low) specific gravity. Creatinine below 20 mg/dL suggests the sample may be diluted, either from drinking excessive water or from adding liquid to the cup. Abnormal pH values can indicate a chemical adulterant was mixed in. Labs also run tests for oxidizing agents, which are substances sold specifically to destroy drug metabolites in urine. If physical characteristics look unusual, or if internal lab standards behave unexpectedly during testing, additional validity tests are triggered automatically.
Clinical Testing vs. Legal Testing
The purpose behind the test shapes how it’s handled. In a clinical setting, the goal is speed: a doctor needs results quickly to guide treatment decisions, and the patient can always provide another sample if something looks off. Results are reported automatically and used for medical care.
Forensic or legal testing operates under much stricter rules. The sample follows a documented chain of custody from collection to result. A scientist reviews the findings, subjects them to peer review, and prepares a formal report. That scientist may also testify in court about the results. The collection, handling, and analytical methods must all be defensible under legal scrutiny, which is why confirmatory testing with GC-MS is non-negotiable in these cases. Workplace drug tests fall somewhere in between, following chain-of-custody protocols but using the results for employment decisions rather than criminal proceedings.